D. Boral Capital Reiterates “Hold” Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “hold” rating reiterated by analysts at D. Boral Capital in a research report issued on Thursday, MarketBeat.com reports.

A number of other equities research analysts also recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, GeoVax Labs presently has an average rating of “Reduce” and a consensus price target of $150.00.

GeoVax Labs Price Performance

GOVX opened at $1.24 on Thursday. The company has a market capitalization of $2.26 million, a price-to-earnings ratio of -0.04 and a beta of 3.81. GeoVax Labs has a 1-year low of $1.14 and a 1-year high of $34.75. The business has a 50 day moving average price of $1.59 and a two-hundred day moving average price of $6.33.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share for the quarter. Equities analysts expect that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

A number of institutional investors have recently made changes to their positions in GOVX. Sabby Management LLC bought a new position in GeoVax Labs during the third quarter worth $313,000. Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs in the 4th quarter worth approximately $104,000. Jane Street Group LLC acquired a new stake in shares of GeoVax Labs during the 4th quarter worth approximately $99,000. Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the third quarter valued at approximately $253,000. Finally, HRT Financial LP bought a new stake in shares of GeoVax Labs during the fourth quarter valued at approximately $31,000. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.